摘要
目的探讨质子泵抑制剂(PPI)在急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)后的应用。方法 ACS患者335例,PCI后均予阿司匹林+氯吡格雷双联抗血小板治疗。分为PPI组(T组,270例)和对照组(C组,65例)。T组分为四个亚组,分别加用埃索美拉唑(T1组,71例)、泮托拉唑(T2组,64例)、雷贝拉唑(T3组,65例)和奥美拉唑(T4组,70例)。术后12个月复查,记录不良事件发生情况。结果术前五组患者基本资料和病情相仿(P>0.05)。随访12个月,五组再狭窄情况及管腔丢失相仿,心血管事件和消化道出血等均无统计学差异(P>0.05)。结论ACS患者PCI后双联抗血小板治疗过程中,加用PPI预防消化道出血,不增加心血管事件发生。
Objective To investigative the application of proton pump inhibitors （PPIs） in patients with acute coronary syndrome （ACS） after percutaneous coronary intervention （PCI）. Methods A total of 335 ACS patients underwent PCI, dual antiplatelet therapy（DAPT） asprin and clopidogrel was assigned into two groups of T（treated with DAPT and PPIs, 270 cases） and C（treated with DAPT alone, 65 cases）. The patients in group T were subdivided into groups of T1 （treated with esomeprazole,71 cases） ,T2（pantoprazole, 64 cases） ,T3 （rabeprazole, 65 cases） and T4 （omeprazole, 70 cases）. The patients were followed up for 12 months and adverse events were recorded. Results The basic data of 5 groups were similar before PCI（P〉0. 05）. There were no significant differences in the restenosis, lumen lost and the cardiovascular events, gastrointestinal bleeding events among five groups during follow up（P〉0. 05）. Conclusion On the basis of DAPT, additional use of PPIs for preventing recurrence of gastrointestinal bleeding events does not increase the occurrence of cardiovascular events.
出处
《江苏医药》
CAS
北大核心
2013年第22期2731-2734,共4页
Jiangsu Medical Journal
基金
无锡市科技局计划项目(CSZ00N1131)
